The Pleural Diseases market report also offers comprehensive insights into the Pleural Diseases market size, share, Pleural Diseases epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Pleural Diseases market size growth forward.
Some of the key highlights from the Pleural Diseases Market Insights Report:
Nivolumab and Ipilimumab Combination: In October 2020, the FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the first-line treatment of adults with unresectable MPM. This approval was based on a clinical trial demonstrating a median overall survival of 18.1 months for patients receiving the combination therapy, compared to 14.1 months for those undergoing standard chemotherapy.
Pembrolizumab (Keytruda): In September 2024, the FDA approved pembrolizumab in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for unresectable advanced or metastatic MPM. This decision was supported by Phase 3 trial data indicating a 21% reduction in the risk of death compared to chemotherapy alone.
ACES™ Automatic Continuous Effusion Shunt System: In October 2023, the FDA granted 510(k) clearance for the ACES™ System, an innovative, fully implantable device designed to manage chronic pleural effusion without external catheters or frequent hospital visits. Clinical studies are underway to assess its efficacy and impact on patient quality of life.
Several key pharmaceutical companies, including Chiesi Farmaceutici, Faron Pharmaceuticals, Actelion Pharmaceuticals, Meril Life Sciences, and others, are developing novel products to improve the Pleural Diseases treatment outlook.
As per DelveInsight analysis, the Pleural Diseases market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Pleural Diseases Market Landscape
Pleural Diseases Overview
Pleural diseases affect the pleura, which is the thin, double-layered membrane surrounding the lungs and lining the chest cavity. These diseases can cause inflammation, fluid buildup, or structural issues that affect lung function and cause symptoms like chest pain and difficulty breathing.
Do you know the treatment paradigms for different countries? Download our Pleural Diseases Market Sample Report
Pleural Diseases Epidemiology Segmentation
DelveInsight’s Pleural Diseases market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Pleural Diseases historical patient pools and forecasted Pleural Diseases patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Pleural Diseases Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Pleural Diseases Prevalence
Age-Specific Pleural Diseases Prevalence
Gender-Specific Pleural Diseases Prevalence
Diagnosed and Treatable Cases of Pleural Diseases
Visit for more @ Pleural Diseases Epidemiological Insights
Pleural Diseases Market Outlook
The global pleural diseases market is experiencing significant growth, driven by advancements in medical technology, increasing prevalence of respiratory disorders, and a focus on personalized medicine.
The pleural diseases market is poised for substantial growth, driven by technological advancements, increasing disease prevalence, and rising investments in healthcare infrastructure. The development of personalized medicine, targeted therapies, and minimally invasive procedures is expected to enhance patient outcomes and quality of life.
Pleural Diseases Key Companies
Chiesi Farmaceutici, Faron Pharmaceuticals, Actelion Pharmaceuticals, Meril Life Sciences, and others
For more information, visit Pleural Diseases Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Pleural Diseases Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Pleural Diseases, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Pleural Diseases epidemiology in the 7MM
Pleural Diseases marketed and emerging therapies
Pleural Diseases companies
Pleural Diseases market drivers and barriers
Table of Contents:
1 Pleural Diseases Market Key Comprehensive Insights
2 Pleural Diseases Market Report Introduction
3 Competitive Intelligence Analysis for Pleural Diseases
4 Pleural Diseases Market Analysis Overview at a Glance
5 Executive Summary of Pleural Diseases
6 Pleural Diseases Epidemiology and Market Methodology
7 Pleural Diseases Epidemiology and Patient Population
8 Pleural Diseases Patient Journey
9 Pleural Diseases Treatment Algorithm, Pleural Diseases Current Treatment, and Medical Practices
10 Key Endpoints in Pleural Diseases Clinical Trials
11 Pleural Diseases Marketed Therapies
12 Pleural Diseases Emerging Therapies
13 Pleural Diseases: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Pleural Diseases
16 Pleural Diseases Market Key Opinion Leaders Reviews
18 Pleural Diseases Market Drivers
19 Pleural Diseases Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Pleural Diseases Epidemiology 2032
DelveInsight’s “Pleural Diseases – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Pleural Diseases epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Pleural Diseases Pipeline 2024
“Pleural Diseases Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Pleural Diseases market. A detailed picture of the Pleural Diseases pipeline landscape is provided, which includes the disease overview and Pleural Diseases treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
